Investors in It

Cyverse Capital injects seed and growth capital into best-in-breed, next-gen cyber-security startups. Cyverse Capital builds on the track record of Cyverse AG, the Zug-based firm which distributes next-gen cyber-security technologies to over 100 multinational enterprises in the DACH and Scandinavia.

Eclosion assists entrepreneurs with the necessary resources to bridge the gap between their laboratories and the stage where the start-up

Seed4Equity Investment fund in seed, early growth companies. targets all industries. Switzerland.

SIFEM is the Swiss Development Finance Institution (DFI). It is owned by the Swiss Government and an integral part of Switzerland's International Cooperation Strategy. SIFEM provides long-term financing through financial intermediaries to SMEs and other fast-growing companies in developing countries. It aims to reduce poverty and foster sustainable, inclusive and resilient economies by creating and securing more and better jobs, growing opportunities for the underserved and supporting projects towards a Just Transition. SIFEM aligns its investments with international environmental goals to address the global climate crisis and support emerging markets in achieving low-carbon economic growth. With its investments it contributes to closing financing gaps and mobilising additional private capital for the growth of local companies in developing countries. By the end of 2022, SIFEM's investment portfolio amounts to USD 451m, thereby financing directly and indirectly 612 companies in 80 countries. Since its inception, SIFEM made commitments of almost USD 1.3 billion.

Alven is an independent early-stage venture capital firm managing over $500m, known for backing 130+ startups across 20 years. They focus on supporting European startups with global potential, specializing in sectors like B2C/B2B marketplaces, productivity tools, AI platforms, social & entertainment, financial services, and wellness brands. Some notable investments include Akeneo, Dataiku, Algolia, Happn, MeilleursAgents, and Birchbox. Alven actively seeks innovative startups at the Series A or Seed stage to partner with for long-term success and growth.

Helvetica Capital AG was founded in 2015 as an independent investment firm which arose from the team behind SVC Ltd. for Risk Capital for SMEs, a wholly owned subsidiary of Credit Suisse. Since 2010, our team at SVC Ltd. (in 2018 renamed Credit Suisse Entrepreneur Capital Ltd. or CSEC) has built up an attrac-tive portfolio with direct investments in Swiss SMEs in the venture, growth and later stage areas, which Helvetica Capital continues to manage and further develop as exclusive advisor to CSEC. In addition, in 2019 Helvetica Capital AG was mandated by Credit Suisse as investment advisor to the Swiss Entrepre-neur Fund (SwissEF) with responsibility for the direct investment activities of the fund. Finally, over the past four years Helvetica Capital AG has built up the Entrepreneur-Investor-Platform (EIP) and has already successfully completed six transactions resulting in majority / controlling interest in these companies. The Entrepreneur-Investor-Platform connects the most successful entrepreneurs and investors of Switzerland with attractive SMEs and thus ensures an active, long-term and independent development of these com-panies. Helvetica Capital AG should not be considered a traditional private capital player, but acts as a long-term partner to companies, bringing with it the expertise and network of its entrepreneurial families. The latter, together with Helvetica Capital, directly participate as co-investors and are not dependent on a quick exit.

We're building Energy Artificial General Intelligence (Energy AGI) to automatically and autonomously supply the world with low-carbon energy at stable prices. Our activities concentrate on physical energy, related supply chain flows and infrastructure. Virtus is on a mission to facilitate the Energy Transition, focusing on renewable and low-carbon energy. Our activities concentrate on physical energy, related supply chain flows and infrastructure.

We are OVNI Capital, a Paris-based first-check venture capital firm committed to aliens redefining global markets. We partner with entrepreneurs seeking to invent new markets or disrupt large existing industries, with a crucial focus on early internationalization. We only invest if a company has the potential to be a global market leader with a strong impact on human lives. We favor being the first venture investor, and we follow on our investments. We invest as little as €250k to seed a company and as much as €2M to lead a round. We invest primarily in France and can be followers in other regions.

QBIT Capital is an early-stage venture capital firm with headquarters in Zurich and an office in Los Angeles. We specialize in investing exclusively in Switzerland and Swiss startups. At QBIT Capital, we are pioneering an innovative and disruptive approach to capital investment. Our mission is to identify new and emerging disruptive business opportunities that have the potential for substantial long-term value creation. QBIT Capital is dedicated to driving innovation, supporting entrepreneurship, and creating meaningful impact through strategic investments and partnerships.

4see ventures is a Swiss venture capital firm investing in healthcare, biotech, medtech, digital health, tech, fintech, climate tech mainly in Switzerland. We back entrepreneurs who are disrupting their markets segments. We invest from CHF300k to CHF4.0m in early-stage, mid- and late-stage ventures.

Gentian is an early-stage investment company founded by the Entrepreneurs Elian Kool and Gerhard Gerner. We focus on investments in SaaS platforms, Mobile, Robotics/Drones and adjacent areas we have a passion for. Based in Switzerland, most of our investments are in the DACH region, but with a clear focus on a global market. We invest exclusively in enthusiastic teams, which we support with our experience as Entrepreneurs, as board member or advisor.

Nextech Venture is a global investment management firm based in Zurich, Switzerland, which manages and advises the first world-wide oncology fund, launched in late 2006, fully dedicated to foster leading cancer companies including therapeutics, diagnostics, and medical devices.